EML4 and non-small cell lung carcinoma: Johung et al. analyzed non-small cell lung cancer (NSCLC) patients with brain metastases treated with SRS and found that tumors with EGFR mutations or EML4–ALK translocations rarely recurred in-field, whereas those that lacked such mutations or harbored KRAS mutations were more likely to experience in-field recurrence (14).